** Shares of  drugmaker Cumberland Pharmaceuticals CPIX.O rise 15.04% to $4.36

**  Co says FDA granted fast track status to its experimental drug ifetroban for heart disease tied to Duchenne muscular dystrophy, a muscle‑wasting condition that weakens the heart

**  Co says ifetroban is an oral treatment and has orphan drug and rare pediatric disease tags

** A recent mid-stage study showed a 5.4% improvement in heart function after 12 months of treatment, co says

** U.S. FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical needs

** Duchenne muscular dystrophy affects boys and gradually damages muscles, including the heart, leading to life‑threatening complications

** Shares up ~68% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))